23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Corporate solution
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Welcome to our Corporate client solution

    Here you can administrate your corporate solutions users.

  • Welcome to your subscription for Life Science Focus

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Focus.

  • Click here to go to sign-up
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Try Life Science Focus now
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Egetis receives SEK 5.3 billion takeover bid from US company

Pharmaceutical executives play down AI hype – see no quick path to cures

Sources: AstraZeneca bid $10 billion for Rhythm Pharmaceuticals
Advertisement
In Focus

EU Biotech Act's lead negotiator: “It's now or never”
Sponsored content News from our members
Aurevia

Upcoming Course: Internal Audits Based on ISO 13485 for Medtech Organizations
GRUBER A/S

Gruber delivers technology for demanding production environments
Aurevia

From legacy devices to software IVDs: Medtech Compliance Forum puts the spotlight on IVDR compliance
GRUBER A/S

GRUBER aims to eliminate bottlenecks in pharmaceutical production
Aurevia

What if some of the most influential systems in healthcare are the least regulated?
See all announcements

German Merck divests its US CDMO business
Advertisement

Novo raises outlook amid Wegovy pill succes
Advertisement
People & Careers

They take the helm as Mölnlycke splits in two

Novartis ends BioArctic deal: “Nothing to do with BrainTransporter”
Advertisement
Sponsored content

A Biotech CTO on the Outsourcing Dilemma: “The Stakes Are Extremely High”
Advertisement
Advertisement

Lytix reports positive cancer data – plans larger trial
Advertisement

Major deal gives Fresenius access to 37 biosimilar candidates – “We are doubling down”

AstraZeneca drops two early-stage prostate cancer drugs
Advertisement
In Focus

EU Biotech Act: Extended drug protection sparks debate
Advertisement

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.063|